Table 2 Clinical outcomes by the selected studies
From: Oligometastasis and local ablation in the era of systemic targeted and immunotherapy
Authors (year of publication) | Local Control | Distant progression free survival | Overall Survival | Toxicity |
|---|---|---|---|---|
Theelen et al. (2019) [17] | NS | 6.6 months | 15.9 months | 12 > G3 |
Lesueur et al. (2018) [20] | 64,4% 2 yr | 2,7 months | 11,1 months | 14,4% > G3 |
Chen et al. (2018) [15] | 88% 1 yr | 2.3 months | 24,7 months | 16% > G3 |
Schapira et al. (2017) [21] | 100% 1 yr | N.S. | 17.6 months | 0 ≥ G4 |
Bauml et al. (2019) [19] | N.S. | 19.1 months | 41.6 months | 5 > G3 |
Hubbeling et al. (2018) [22] | N.S. | N.S. | N.S. | 9 > G3 |
Verma et al. (2018) [16] | N.S. | N.S. | N.S. | 25 > G3 |